experiance

SMG brings hands-on experience developing and growing preventive screening programs built around CT and MRI imaging, laboratory testing and early disease detection. Our work connects clinical services with patient education, market positioning and the operations needed to build a sustainable business.

From individual screenings to comprehensive longevity programs, SMG helps organizations define their offerings, explain the benefits and limitations of different tests, develop pricing and marketing strategies, and build referral and strategic partnerships. Experience spans direct-to-consumer services, employer and union programs, and expanding a nationally recognized platform across three locations.

Patients seeking alternatives to surgery are exploring services involving PRP, stem cells, exosomes and certain peptides. These offerings intersect with self-directed, cash-pay healthcare, but differ in their intended uses, supporting evidence and regulatory status.

SMG works with suppliers and providers to evaluate opportunities, develop service offerings and explain their potential benefits and limitations clearly. We follow regulatory developments and assess clinical and marketing claims—helping organizations distinguish emerging possibilities from established evidence and build responsible, commercially viable programs.

AI spans both the clinical practice of medicine and the business supporting it—from applications in imaging, clinical workflows and decision support to customer service, marketing, lead generation, research and report writing.

SMG helps organizations evaluate where AI can add practical value and how to incorporate it into existing processes. Our approach connects technology with business priorities, staff capabilities and human oversight, while considering accuracy, privacy and compliance. The goal is better information, more efficient operations and a stronger patient and customer experience.

Self-pay and self-directed care extend beyond individual health decisions to the way healthcare services are offered, purchased and delivered. Providers are developing cash-pay services alongside traditional reimbursement models, creating new opportunities that require a different approach to pricing, positioning and the patient experience.

SMG brings experience building direct-to-consumer healthcare programs, developing service offerings and connecting clinical value with what people understand and are willing to purchase. Our work spans business models, patient education, marketing, strategic partnerships and operational execution.

David’s book, Self-Directed Care: Revolution or Evolution?, explores this intersection of consumer choice, provider adaptation and the business of healthcare. 

From GLP-1 medications to a broader range of emerging applications, peptides have become an important focus across healthcare and longevity. 

The landscape includes FDA-approved medications and unapproved compounds, making careful evaluation of clinical evidence, regulatory status and marketing claims essential.

SMG follows these developments to help organizations assess opportunities, question unsupported claims and connect business strategy with clinical and regulatory realities. David’s book, The Peptide Revolution, explores this evolving field and the questions it raises for providers, businesses and consumers.

Laboratory testing spans clinical care and direct-to-consumer services, connecting disease detection, treatment decisions and personalized health insights. SMG’s experience includes working with diagnostic laboratories across cancer-related testing, bacterial identification, antibiotic susceptibility, cancer genetics, pharmacogenomics, drug screening and medication monitoring.

Our work connects advances in in vitro diagnostics—including PCR and next-generation sequencing—with market needs, provider adoption and consumer education. SMG helps laboratories define their value, develop commercial strategies and build partnerships, while considering reimbursement, cash-pay opportunities and operational requirements.

 SMG brings experience developing programs that connect diagnostic insights, patient education and personalized health services. 

Our work spans program design, positioning, strategic partnerships and commercial execution—helping organizations translate complex offerings into understandable value for patients and a sustainable business model. 

Remote patient monitoring connects care beyond the clinic through devices that transmit patient health data to providers. Adoption continues to expand: Medicare payments for these services exceeded $500 million in 2024, according to a 2025 report from the U.S. Department of Health and Human Services Office of Inspector General. oig.hhs.gov

SMG works with software developers, device manufacturers, revenue cycle management organizations and remote care teams to develop commercial strategies, build partnerships and support adoption. Our experience spans remote monitoring and chronic care management, connecting technology with provider workflows, patient engagement and sustainable business models.

Employers spend millions of dollars on healthcare for their employees and over 80% is spent on chronic disease; cancer and heat disease. In addition, loss in productivity, absenteeism, disability or the loss of a key employee adds to those costs.

SMG developed a diagnostic employee benefit program that identifies asymptomatic, previously undiagnostic high risk employees with early signs of heart disease and cancer. Early detection and treatment is the key to survival and lower costs. 

Chronic diseases affect 6 in 10 adult Americans, of which, 43% have more than one chronic condition. The Centers for Disease Control and Prevention estimates that chronic conditions account for most deaths in the U.S. and were responsible for 90% of healthcare expenditures in 2016.

SMG clients focus on the prevention, detection and treatment of chronic conditions helpingh improve outcomes, lower risk of motality and save money. 

Antibiotic resistance has reached pandemic proportions and is a leading concern for world health agencies. Over-use and mis-use of antibiotics, as a result of empiric, prophylactic prescribing is cited as a leading cause. 

Our clients are leading the fight on early detection and diagnosis of bacterial infections with precision antibitic therapy for only those patients that need treatment.  

Infectious disease is a world health concern and a leading cause of death, hospitalization and treatment costs.  Demand for faster, more accurate and cost effective diagnostic testing has resulted in significant investments in the clinical laboratory space.